GLP-1 C + GLP-1 S Combination — Cagrilintide / Semaglutide 5mg Blend
CagriSema Combination Stack — The Amylin + GLP-1 Dual Mechanism Fat Loss Research Frontier
The GLP-1 C + GLP-1 S combination delivers both cagrilintide (long-acting amylin analog) and semaglutide in a single lab bundle — investigating the synergistic weight loss potential of combined amylin/GLP-1 dual mechanism science that Phase 2 trials suggest may exceed either agent alone.
Secure checkout · Third-party tested · Affiliate link
CagriSema Combination Stack — The Amylin + GLP-1 Dual Mechanism Fat Loss Research Frontier
Cagrilintide (GLP-1 C) is a long-acting amylin analog developed by Novo Nordisk for use in combination with semaglutide as "CagriSema." Amylin is a pancreatic peptide co-secreted with insulin that acts centrally on the area postrema and hypothalamus to reduce food intake, slow gastric emptying, and reduce glucagon secretion. Unlike GLP-1 agonists that work primarily through GLP-1R, amylin analogs activate amylin receptors (AMY1-3) — entirely independent receptors. Combining amylin receptor and GLP-1 receptor activation therefore provides complementary, non-redundant weight loss mechanisms. Phase 2 SCALE data showed the CagriSema combination achieving ~15% weight loss vs ~9% for semaglutide alone.
Cagri + Sema Combo Documented Benefits: 5 Documented Mechanisms
Dual Non-Redundant Mechanism Action
Amylin receptor (AMY1-3) activation by cagrilintide operates through entirely different neural circuits than GLP-1R — providing complementary appetite suppression without receptor desensitization competition.
Superior Weight Loss vs GLP-1 Monotherapy
Phase 2 data shows CagriSema achieving ~15% weight loss vs ~9% for semaglutide alone and ~8% for cagrilintide alone — demonstrating true synergistic effect beyond simple addition.
Area Postrema Satiety Amplification
Amylin receptors concentrated in the area postrema (a brain region uniquely exposed to circulating peptides) provide powerful central satiety signals independently of hypothalamic GLP-1R circuitry.
Glycemic Control Enhancement
Cagrilintide's amylin activity adds glucagon suppression and gastric emptying delay to semaglutide's insulin secretion amplification — providing multi-mechanism glycemic control in metabolic science models.
Premium Grade Combination Protocol
Pre-combined lab bundle enables precise, standardized investigation of the cagrilintide/semaglutide combination without separate weighing and reconstitution requirements.
How Cagri + Sema Combo Works: Molecular Mechanism & Pathway
Cagrilintide binds amylin receptors (CGRP receptor + RAMP1/2/3 complexes) in the area postrema, hypothalamus, and GI tract. AMY receptor activation increases intracellular cAMP and activates MAPK pathways to suppress food intake, reduce glucagon secretion, and delay gastric emptying. These effects are additive with semaglutide's GLP-1R-mediated appetite suppression, creating synergistic central satiety signaling from two anatomically distinct receptor populations in the brain's appetite control networks.
◈ Key Highlights
- Phase 2 CagriSema trial: ~15% weight loss vs ~9% semaglutide alone at comparable doses
- Currently in Phase 3 REDEFINE program targeting 25%+ weight loss
- Amylin receptor mechanism completely independent of GLP-1R pathway — true mechanistic synergy
- Potential to challenge retatrutide for maximum weight loss magnitude in ongoing Phase 3 data
Ideal For
- CagriSema combination mechanism science
- Amylin receptor biology investigation
- Comparative dual vs triple agonist studies
- Advanced appetite regulation science
Intended for laboratory use only. Not for human or animal consumption. Not FDA approved. Handle in appropriate lab settings only.
